Core Viewpoint - Meihua Biotechnology is advancing steadily in the synthetic biology sector through diversified expansion and deepening development, highlighted by its recent acquisition of assets from Kyowa Hakko Bio, which will enhance its amino acid product lines and operational capabilities [1][2]. Group 1: Acquisition Details - The acquisition agreement between Meihua Biotechnology and Kyowa Hakko Bio is set to be completed by July 1, 2025, with a final transaction value of approximately 16.8 billion yen, equivalent to about 833 million yuan [1]. - The cash reserves of the target assets are estimated at around 11.3 billion yen, or approximately 560 million yuan, as of June 30, 2025 [1]. Group 2: Product and Market Expansion - Post-acquisition, the company will introduce various new amino acids and fermentation strains, including arginine, histidine, serine, citrulline, ornithine, and hydroxyproline, along with patents related to these amino acids [2]. - The transaction will enable the company to extend its industrial chain, enhancing its fermentation and refinement capabilities for high-value pharmaceutical-grade amino acids [2]. Group 3: Strategic Positioning - Meihua Biotechnology aims to implement its overseas development strategy through this acquisition, gaining multiple domestic and international production entities [2]. - The company will also acquire the ability to produce three types of HMO products through a precision fermentation platform, along with the associated intellectual property rights [2]. Group 4: Industry Background - Kyowa Hakko Bio has a long-standing reputation in the global synthetic biology field, with over 70 years of technological expertise and numerous patents in amino acid and HMO product development [3]. - The company has successfully commercialized various amino acids and HMO products, including 2'-fucosyllactose, 3'-sialyllactose, and 6'-sialyllactose [3]. Group 5: Financial Performance - Meihua Biotechnology reported a revenue of 25.069 billion yuan and a net profit of 2.74 billion yuan for 2024, with a significant year-on-year growth of 35.52% in net profit for the first quarter of 2025 [3].

Core Viewpoint - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on industrial ecological development and the transfer of scientific and technological achievements [1]. Group 1: Conference Overview - SynBioCon 2025 is organized by DT New Materials and supported by various academic and industrial organizations, aiming to facilitate over 1,000 connections between research institutions and startup projects [1]. - The conference will feature a special event showcasing 100 innovative achievements in synthetic biology manufacturing, promoting efficient technology transfer [1][10]. Group 2: Featured Project - The project "Biological Synthesis of L-Piperidine Carboxylic Acid" from Chongqing University focuses on producing L-PA, a crucial non-protein amino acid used in pharmaceuticals [6]. - The first-generation E. coli cell factory achieved a yield of approximately 52.68 g/L with a conversion rate of 90% and a productivity of 2.52 g/L-h, which is considered world-leading [6]. - The second-generation strain using yeast improved the yield to 75.54 g/L and has three core invention patents authorized [6][9]. Group 3: Technical Advantages - The engineered strain has over 90% stability and higher utilization of lysine due to pathway knockout and promoter optimization [8]. - The process benefits from shorter reaction times, lower temperatures to prevent contamination, and 100% optical purity of the product [8]. - The cost-effectiveness of the technology route contributes to high economic benefits [8]. Group 4: Intellectual Property and Collaboration - The project has three authorized core invention patents and offers collaboration opportunities through project partnerships, technology transfers, and joint laboratories [9]. Group 5: Conference Themes - The conference will explore the "1+4" theme, focusing on AI and bio-manufacturing, with applications in green chemicals, new materials, future food, future agriculture, and beauty raw materials [12]. - It aims to discuss the trends in bio-manufacturing during the 14th Five-Year Plan and identify innovative technologies and products that will sustain the industry's vitality [12]. Group 6: Service Platform - A global service platform for bio-based and bio-manufacturing industries is available at www.bio-basedlink.net [15].

Group 1 - The AI + Synthetic Biology Industry Chain Innovation Integration Conference was held in Hangzhou, featuring over 100 companies from sectors such as biomedicine, food and beverage, and health products [1] - Companies like Enhe Bio, Yanjin Bio, BGI, and Zhejiang University International Innovation Center showcased their latest achievements and application cases in the "AI + Synthetic Biology" field, covering multiple aspects from technology research and development to industrial application [1] - Synthetic biology, as an emerging technology, has broad application prospects in medicine, agriculture, and food, addressing issues like high costs, low efficiency, and pollution in traditional food manufacturing [1] Group 2 - There exists an information barrier between the technology and application ends, where technology companies possess advanced techniques but application companies struggle to connect with these resources, leading to a mismatch between demand and supply [2] - The conference aimed to bridge the gap between research and application enterprises, facilitating the dual-channel connection of "technology supply - scenario demand" in the synthetic biology industry [2] - Hangzhou has actively laid out the synthetic biology industry, implementing special policies and a three-year action plan, resulting in the establishment of 172 related companies covering the complete industrial chain from strain design to terminal application, with an expected industry output value of approximately 20 billion yuan in 2024 [2]

Core Insights - Company reported a contradictory financial performance for 2024, with revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, but a net profit of 190 million yuan, down 57.8% [2] - The company addressed key regulatory concerns regarding overseas revenue authenticity, sharp decline in gross margin, and abnormal inventory growth in a detailed response to the Shanghai Stock Exchange [2][3] Revenue and Market Performance - The company achieved overseas revenue exceeding 1 billion yuan for the first time, reaching 1.032 billion yuan, accounting for 47.39% of total revenue, with a year-on-year growth of 30.34% [3] - The European market was the primary source of overseas revenue, contributing 429 million yuan, while the Americas and Asia accounted for 294 million yuan and 309 million yuan, respectively [3] - The growth in revenue was primarily supported by the top five overseas customers, whose sales reached 418 million yuan, an increase of 111 million yuan from the previous year [3] Pricing Pressure and Gross Margin Decline - The company acknowledged significant price declines due to intensified market competition, particularly for L-valine, leading to a sharp drop in average selling prices for amino acids and vitamins [4][5] - The average selling price of amino acid products fell from 19,000 yuan per ton in 2023 to 15,600 yuan per ton in 2024, a decrease of 17.89%, while vitamin products saw a 54.09% drop from 84,300 yuan per ton to 38,700 yuan per ton [4] - The gross margin plummeted from 40.52% to 24.92%, a decline of 15.6 percentage points, raising concerns from the Shanghai Stock Exchange [4] Inventory and Financial Indicators - The company's inventory value surged to 407 million yuan, an increase of 80.09% year-on-year, attributed to increased stock of goods and raw materials [5][6] - Inventory turnover rate decreased from 6.37 times to 5.16 times, indicating a potential risk of impairment due to high inventory levels amid declining prices [5][6] Expansion and Future Projects - Despite the challenges, the company is aggressively expanding its production capacity, with construction projects valued at 1.592 billion yuan, including a 50,000-ton bio-based succinic acid project and a 50,000-ton bio-based propylene glycol project [7] - The company anticipates that these projects will begin operations in the second half of 2025, although there are concerns about the timely realization of benefits from these investments [8] Strategic Initiatives - The company is pursuing collaborations to enhance its supply chain, including forming a "Bio-based Polyester Textile Industry Alliance" and signing strategic agreements with BASF for product development [9] - Additionally, the company secured a 20-year exclusive license for the bio-based production of tryptophan technology from Eurobio [10]

Core Viewpoint - Israeli scientists from the Weizmann Institute have developed a new computer algorithm based on enzyme principles to design highly efficient synthetic enzymes, achieving 100 times the efficiency of AI-designed enzymes, marking a new phase in "on-demand" enzyme customization [1][2]. Group 1: Algorithm Development - Traditional computer algorithms for enzyme design are often inefficient and require extensive laboratory optimization [2]. - The research team utilized "Kemp elimination" as a case study, collecting natural enzyme data and decomposing protein sequences into fragments, which were then recombined to identify the optimal chemical "skeleton" [2]. - The algorithm challenged the traditional belief that enzyme active sites require cyclic amino acids, showing that non-cyclic structures can be more efficient, significantly enhancing catalytic efficiency [2][3]. Group 2: Synthetic Enzyme Characteristics - The resulting synthetic enzyme differs from natural enzymes by over 140 amino acid sequences but demonstrates comparable catalytic efficiency [3]. - The current synthetic protein structure remains simpler than natural enzymes, with future research focusing on complex multi-step reactions, such as those catalyzed by the key photosynthetic enzyme rubisco [3]. Group 3: Future Directions - While AI protein design has been prevalent over the past decade, it primarily mimics existing enzymes; the new algorithm constructs enzymes based on physical principles [3]. - The research team acknowledges that AI is irreplaceable for certain protein designs but struggles with complex catalytic reactions, suggesting a need for complementary approaches to achieve optimal enzyme designs [3]. Group 4: Upcoming Events - The 4th Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and biological manufacturing, along with four application areas: green chemicals and new materials, future food, future agriculture, and beauty raw materials [5].

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan period, highlighting innovative technologies and products that will sustain the industry's vitality [1]. Group 2: Organizers and Highlights - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. - Key highlights include forums on biomanufacturing trends, youth innovation sharing, project roadshows, and participation from leading enterprises, top universities, and investment institutions [4]. Group 3: Agenda and Special Activities - The first day features a closed-door high-level seminar focusing on the development trends and growth points of biomanufacturing, with 30 industry leaders and experts invited [7]. - The second and third days will include a macro forum on biomanufacturing, covering the overall trends and progress in the industry [10]. Group 4: Specialized Forums - Specialized forums will cover topics such as green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - The forums will discuss various aspects of biomanufacturing, including the development of bio-based chemicals, green manufacturing technologies, and the application of AI in industrial processes [11]. Group 5: Project Roadshows and Talent Engagement - The conference will feature project roadshows aimed at connecting head parks and investment institutions with innovative biomanufacturing projects [10]. - A youth forum will be held to discover potential teams and technologies in biomanufacturing, providing a platform for efficient talent and collaboration exchanges [10].

Core Viewpoint - Shenzhen is focusing on high-quality economic development, aiming for a GDP growth target of 5.5% in 2024, while showcasing its strengths in various emerging industries such as robotics, low-altitude economy, and synthetic biology [5][8]. Group 1: Economic Development and Growth Targets - Shenzhen's GDP exceeded 3.68 trillion yuan in 2024, with a land area of less than 2000 square kilometers [5]. - The city is committed to high-quality development, emphasizing the importance of local street-level economic contributions [5][6]. Group 2: Robotics Industry - Shenzhen is emerging as a hub for robotics, with companies like Zhongqing Technology showcasing innovations such as humanoid robots and advanced robotics capabilities [6][7]. - The "Robot Bay" area in Nanshan District is home to numerous high-tech enterprises and research institutions, fostering a collaborative innovation environment [7][8]. Group 3: Low-Altitude Economy - The low-altitude economy is recognized as a strategic emerging industry in Shenzhen, with initiatives like drone delivery and air taxis becoming increasingly common [8][9]. - The Bao'an District is developing a low-altitude economic industrial park, which serves as a public service platform for low-altitude enterprises [9]. Group 4: Synthetic Biology - Synthetic biology is a key focus area for Shenzhen, with the Guangming District leading in this field and establishing a strong industrial base [10][11]. - The New Lake Street in Guangming is a significant cluster for synthetic biology, housing various innovation centers and research facilities [10]. Group 5: Infrastructure and Urban Development - The Shenzhen Financial Culture Center is being developed as a new financial hub, enhancing the city's urban landscape and economic potential [12]. - Various districts are actively promoting industrial space development to support high-quality economic growth, with a focus on advanced manufacturing [13]. Group 6: Consumer Growth and Economic Activity - The city is witnessing a surge in consumer activity, particularly in the Fuyuan District, which has maintained the highest retail sales in Shenzhen [14]. - Events like the "Four Seas Family Grand Parade" have significantly boosted tourism and retail sales, indicating a vibrant consumer market [14]. Group 7: Support for Enterprises - Shenzhen's streets are adopting diverse service models to support local enterprises, enhancing the overall business environment [15][16]. - The government is facilitating collaboration between leading companies and local businesses to drive innovation and efficiency [17].

2'-FL：母乳关键成分，赋能健康营养 作为母乳中含量最高（约30%）的人乳寡糖，2'-FL具有显著的营养与医学价值：促进婴幼儿生长发育及认知能力；增强 免疫力，抗病毒、抗过敏；调节肠道菌群平衡。其应用已覆盖多国婴幼儿配方奶粉，是极具潜力的新型营养强化剂。 未来食品&农业 | 柯泰亚 关于柯泰亚 【SynBioCon】 获 悉 ， 柯泰亚生物科技（上海）有限公司（以下简称"柯泰亚"）宣布，其自主研发的母乳低聚糖 （HMO）核心产品 2'-岩藻糖基乳糖 (2'-FL) 正式通过美国食品药品监督管理局 (FDA) 的GRAS (一般认为安全， Generally Recognized As Safe) 认证。 2025年初柯泰亚向FDA提交了关于2'-FL作为食品配料的申请，2025年6月18日收到FDA的"No Question Letter"， 确认柯泰亚2'-FL可作为食品添加剂应用于婴儿配方奶粉、儿童食品及传统食品及饮料 。此举标志着柯泰亚成为国内少数 获得该认证的本土企业，其研发创新、生产质量与安全管控体系获得国际权威认可。 此次认证是柯泰亚凭借自主知识产权进军全球HMO市场的重要突破。获得FDA GR ...

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan and identify innovative technologies and products that can sustain the industry's vitality [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detai Zhongyan Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. Group 3: Highlights of the Conference - The conference will feature forums and closed-door activities to gain insights into the development trends of biomanufacturing during the 14th Five-Year Plan, exploring new products, technologies, and collaborations [4]. - There will be over 100 financing project roadshows to discover new cooperation opportunities [4]. - Key industry players, top universities, and capital from various sectors will gather to discuss advancements in biomanufacturing [4]. Group 4: Special Activities and Agenda - The first day will include a closed-door seminar focusing on the development trends and growth points of biomanufacturing, inviting 30 industry leaders and experts for in-depth discussions [7]. - The second and third days will feature a macro forum on biomanufacturing, covering the development trends and progress of policies related to the industry [10]. Group 5: Specialized Forums - The conference will host specialized forums on various topics, including green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - Each forum will address specific themes such as the development of bio-based chemicals, green manufacturing technologies, and the application of AI in biomanufacturing processes [11].

2025年夏季达沃斯论坛6月24日到26日在天津举行。论坛期间，多位跨国企业负责人表示，中国庞大的 市场和新产业新技术的快速发展，将为跨国企业在中国的发展提供源源不断的动能。与会嘉宾表示，中 国拥有广阔的市场和强大的科研能力，这些将坚定跨国企业在中国投资的信心。随着中国在人工智能、 人形机器人等领域的快速发展，跨国企业也找到了与中国企业合作的新方向。此外，脑机接口、合成生 物等未来产业在中国的快速布局，也让跨国企业期待在相关领域能有更多合作。（央视新闻） ...